Trial Profile
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms PHOENIX
- 15 Apr 2020 Status changed from recruiting to suspended.
- 19 Feb 2020 Planned End Date changed from 1 Aug 2023 to 1 Dec 2025.
- 19 Feb 2020 Planned primary completion date changed from 1 May 2021 to 1 Mar 2023.